RAD50 and neoplasm: To assess the influence of specific gene mutations on disease course (germline and/or somatic variants in PIK3 and/or AKT, PALB2, BRIP1, RAD50, RAD51, RAD54, RB1, SPOP, Wnt/B‐catenin pathway, CDK12, and MMR genes: MLH1, MSH2, MSH6, PMS2, and EPCAM as well as subjects with tumour mutational burden‐high (TMB‐H) prostate cancer